{"disease":{"id":"breast-cancer-patients","name":"breast cancer patients"},"drugs":{"marketed":[{"drug_id":"trastuzumab-emtansine","indication_name":"Treatment of HER2-positive breast cancer in patients for whom trastuzumab and pertuzumab are indicated","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kadcyla","generic_name":"trastuzumab-emtansine","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"900","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent."},{"drug_id":"trastuzumab-emtansine","indication_name":"Treatment of HER2-positive unresectable or metastatic breast cancer in patients who have received prior anti-HER2-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kadcyla","generic_name":"trastuzumab-emtansine","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"900","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent."},{"drug_id":"trastuzumab-emtansine","indication_name":"Treatment of HER2-positive breast cancer in patients who have received prior trastuzumab-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kadcyla","generic_name":"trastuzumab-emtansine","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Antibody-drug conjugate","quality_score":10,"revenue":"900","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azd5363","indication_name":"Triple-negative breast cancer with disease progression on or after chemotherapy in the neoadjuvant or adjuvant setting and/or in patients with measurable disease by RECIST v1.1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azd5363","generic_name":"azd5363","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"AKT","drug_class":"phosphatidylinositol 3-kinase (PI3K) inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":20,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05809128","title":"Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"IRCCS SYNLAB SDN","has_results":false},{"nct_id":"NCT05009849","title":"Role of Exercise in Breast Cancer Patient Undergoing Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":850,"lead_sponsor_name":"Tata Memorial Centre","has_results":false},{"nct_id":"NCT05801705","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06685562","title":"The 4D PICTURE Project: Evaluating Metro Mapping As a Method to Support Shared Decision Making in Oncology","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT06044623","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":495,"lead_sponsor_name":"Region Örebro County","has_results":false},{"nct_id":"NCT04296370","title":"A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":474,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04480203","title":"Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions","phase":"NA","overall_status":"RECRUITING","enrollment_count":390,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT06629012","title":"Autologous Nerve Graft Breast Reconstruction Neurotization","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04304924","title":"Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07253987","title":"Cancer Survivors Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Masaryk Memorial Cancer Institute","has_results":false},{"nct_id":"NCT05189717","title":"A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":156,"lead_sponsor_name":"Shandong Suncadia Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05802342","title":"A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06427044","title":"Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":143,"lead_sponsor_name":"Lu Hua","has_results":false},{"nct_id":"NCT06837792","title":"Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":141,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT05051956","title":"Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?","phase":"","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Namik Kemal University","has_results":false},{"nct_id":"NCT07254416","title":"A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07355361","title":"Huaier Granule and Proteinuria","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06764940","title":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Biostar Pharma, Inc.","has_results":false},{"nct_id":"NCT07037576","title":"Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT04581967","title":"Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Damanhour University","has_results":false},{"nct_id":"NCT06186700","title":"Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT07132749","title":"NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Yeon Hee Park","has_results":false},{"nct_id":"NCT06823440","title":"Prevention of CIPN Using Compressive Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Martina Lojova","has_results":false},{"nct_id":"NCT05590559","title":"Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block in Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction - a Non-inferiority Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT04654195","title":"Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Damanhour University","has_results":false},{"nct_id":"NCT03771183","title":"Loreline Study: Characterization of Long Responders Under Eribuline","phase":"","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Centre Jean Perrin","has_results":false},{"nct_id":"NCT05836077","title":"Pecha Kucha Method Effects on Posttraumatic Growth and Psychological Resilience","phase":"NA","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Istanbul Sabahattin Zaim University","has_results":false},{"nct_id":"NCT07349459","title":"Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT07041762","title":"Rhomboid Intercostal Block With Sub-Serratus Plane Block Versus Erector Spinae Block","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT07357207","title":"Video-immunotherapy: a New Approach in Breast Cancer Treatment","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":80,"lead_sponsor_name":"Izmir Biomedicine and Genome Center","has_results":false},{"nct_id":"NCT07113964","title":"QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":79,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07437144","title":"Exploring the Effects of Shangshou Daoyin Method on Improving Sleep Quality, Quality of Life, and TCM Constitution in Breast Cancer Patients With Insomnia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":76,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT06711978","title":"Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Pusan National University Yangsan Hospital","has_results":false},{"nct_id":"NCT03046238","title":"Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"South Egypt Cancer Institute","has_results":false},{"nct_id":"NCT06986213","title":"Heart Pillow - Chemoteraphy","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":60,"lead_sponsor_name":"José Manuel Afonso Moreira","has_results":false},{"nct_id":"NCT06183164","title":"Awareness Based Stress Reduction Program Applied to Breast Cancer Patients Receiving Chemotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Firat University","has_results":false},{"nct_id":"NCT06529458","title":"Effects of Acupressure and Aromatherapy on Nausea and Vomiting Severity, Anxiety and Comfort Level","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Setenay Batır","has_results":false},{"nct_id":"NCT06038539","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":55,"lead_sponsor_name":"Biocon Biologics UK Ltd","has_results":false},{"nct_id":"NCT07405008","title":"Laser Acupuncture on Carpal Tunnel Syndrome .","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06172088","title":"Exploratory Study Therapeutic Fasting Reduce Physical Limitations, Quality of Life During Aromatase Inhibitor Therapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT05112341","title":"Adjuvant Whole Breast Irradiation in Five Fractions Versus Fifteen Fractions in Early Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT05560308","title":"Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03969524","title":"Functional MRI in Predicting Response to Chemotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07135960","title":"Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery)","phase":"","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Portsmouth Hospitals NHS Trust","has_results":false},{"nct_id":"NCT06884852","title":"Ultrasound-guided Multilevel Erectorspinae Plane Block Versus Thoracic Epidural Analgesia for Prevention of Post Mastectomy Pain Syndrome for Breast Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"National Cancer Institute, Egypt","has_results":false},{"nct_id":"NCT06546787","title":"The Effect of Interpersonal Relationships Psychotherapy on Breast Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Koç University","has_results":false},{"nct_id":"NCT03304756","title":"Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Instituto Nacional de Cancer, Brazil","has_results":false},{"nct_id":"NCT06254066","title":"Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT07064317","title":"Catheter Tip Position and Contrast Distribution Following Paravertebral Catheter Insertion: a CT Study","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Ziekenhuis Oost-Limburg","has_results":false},{"nct_id":"NCT03684135","title":"Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Centre Jean Perrin","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}